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Thyroid transcription factor (TTF-1) is a tissue-specific nuclear transcription factor expressed developing thyroid, respiratory
epithelium, and diencephalon. TTF-1 is thought to be expressed specifically in most thyroid tumors and in a significant subset
of pulmonary neoplasms. However, recent studies on its expression in extrapulmonary carcinomas have demonstrated that TTF-1
is not as specific for lung and thyroid carcinomas as was previously thought: positivity of this marker can be observed, although
much less frequently, in some carcinomas arising in other organs, such as the ovaries, endometrium, colon, and breast, as well as
in some tumors of the central nervous system. Case reports of patients with TTF-1-positive colon adenocarcinoma are present in
medical literature, but there are only a few cases of TTF-1-positive rectal adenocarcinoma.We present the case of a patient with rectal
adenocarcinoma with lung metastasis found to be TTF-1-positive on immunohistochemistry. A review of the available literature is
also included.
1. Introduction
The thyroid transcription factor (TTF-1) is a nuclear protein,
part of the Nkx2 gene family. Its expression in normal tissues
is restricted to the thyroid and pulmonary epithelium [1,
2]. In lung adenocarcinoma, TTF-1 has been considered a
highly sensitive (up to 84% sensitivity) and specific marker
(85–100% specificity) for primary lung adenocarcinoma,
and it is therefore used as a reliable tool in distinguishing
primary lung adenocarcinoma from other malignancies [3].
Nevertheless, in recent years, several studies have highlighted
that some cancer arising in other organs, in particular in
the intestinal tract, can manifest positivity for this marker
[1, 2, 4]. Rare cases of patients with TTF-1-positive rectal
adenocarcinoma have been reported. Here, we present a case
of rectal cancer with TTF-1-positive lung metastasis which
highlights the importance of using additional panels.
2. Case Presentation
A 69-year-old patient was diagnosed with a rectal ade-
nocarcinoma (G2) on biopsy after an endoscopic control
examination in 2013. He was treated first with radio adjuvant
chemotherapy and subsequently with surgery. This combi-
nation of treatments has led to a complete response: any
residual areas of cancer and lymph node involvement were
documented on the surgical piece (yPT1N0 A/I G2 Sec
MANDARD). In 2018, during regular oncological follow-up,
a subpleural pulmonary nodule in lower lobe of the left lung
of about 15x10 mm was detected. Considering the patient's
clinical history, his general conditions, and localization of the
lesion, a surgical resection of the lung was performed. On
the macroscopic exam of the sample, physicians observed a
neoformation of 1.9x1.5x0.6 cm, which is whitish, solid, with
irregular but well-defined margins, 0.6 cm away from the
surgical suture and 0.1 cm from the visceral pleura. Histologic
examination demonstrated an epitheliomorphic neoplasm
with acinar differentiation (Figure 1). The adenocarcinoma
cells were positive for cytokeratin 20 (CK20) and scattered
positivity for caudal type homeobox 2 (CDX2) was found.
TTF-1 was also strongly and diffusely positive. The tumor
cells were negative for CK7 and Napsin A. Retrospective
review of his previous primary tumor tissue showed similar
histologic findings with TTF-1 positivity. On the basis of the
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Figure 1: (a) Representative image of the neoplasm (on the left) with normal healthy tissue (on the right) (×200); (b) CK7 immunohisto-
chemical expression (×200); (c) CK20 immunohistochemical expression (×200); (d) Napsin A immunohistochemical expression (×200); (e)
TTF-1 immunohistochemical expression (×200); (f) Ki67 immunohistochemical expression (×200).
positivity for CK20 and CDX2with negative CK7 and Napsin
A and of the morphology of the lesion, the diagnosis was the
following: metastasis from TTF1-positive primary colorectal
adenocarcinoma.
3. Discussion
Metastasis from CRC adenocarcinoma is a very frequent
event that is present in 20% of patients at the time of diagno-
sis, and an additional 50–60%will develop metastatic disease
at the time of progression [5] (Van Cutsem E, Nordlinger
B, Adam R, Kohne CH, Pozzo C, Poston G, et al.: Towards
a Pan-European Consensus on the Treatment of Patients
with Colorectal Liver Metastases; Eur J Cancer 2006;42:
2212–2221). One of the most common sites of CRCmetastasis
is the lung, and TTF-1 is considered as a highly sensitive and
specific marker to distinguish primary lung adenocarcinoma
from metastatic adenocarcinoma. However, several studies
have highlighted that TTF-1 is not as specific for lung and
thyroid carcinomas as was previously thought as it can be
found to be expressed, although much less frequently, in
some carcinomas arising in other organs and in particular
in gastrointestinal neoplasms [1, 4]. In addition, one aspect
to consider is some variability in detection depending on
the clonal antibody used for testing. There are two clones
for TTF-1 known as SPT24 and 8G7G1 [1]. Both clones
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target the nucleus, but it is proven to be a discrepancy
in intensity staining. Since the beginning of its use, spt24
has shown its ability to bring out the cell nucleus with
immunohistochemical examination. In their study, Penman
et al. have shown how SPT24 has a strong nuclear positivity
in colon carcinomas instead of 8G7G1 [6], a result confirmed
by other studies carried out on a more extensive case series
[7–9]. Colonic carcinomas with nuclear positive for 8G7G1
have been described in literature [10, 11]. What is striking
is the colour intensity of the nucleus, which appears to be
mild.The advancement of immunohistochemical techniques
is unmasking the expression of TTF-1 by neoplasm different
from lung and thyroid ones. The set of evaluated data
would suggest that SP124 antibody seems to have a higher
detection rate than 8G7G1. Nevertheless, an appropriate
and prudent approach to case assessment is fundamental.
Cases of recurrence with metastatic lesions or occult primary
malignancies with pulmonary metastases may constitute a
problemof differential diagnosis. Arrangement of TTF-1 with
CK20, CDX2, and CK7 is prompted to settle the diagnostic
question and the use of SPT24 is suggested for its sensibility.
Finally, if available, concurrent evaluation of the primary
tumor pathology can be of great help in achieving the correct
diagnosis and consequently in offering our patients the most
appropriate treatment. It is the set of findings that leads to the
most correct diagnosis.
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